New indication for Astellas/Medivation's Xtandi from US FDA

11 September 2014
astellas-logo-big

The US Food and Drug Administration has approved a new indication for the use of Japanese drug major Astellas Pharma (TYO: 4503) and Medivation’s (Nasdaq: MDVN) Xtandi (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC).

This new approved use follows a priority review of the supplemental New Drug Application (sNDA) that was based on results of the Phase III PREVAIL trial. The news pushed Medivation’s shares 2.7% higher to $96.89 in after-hours US trading yesterday, while Astellas gained 2.25% to 1,544.5 yen in Japanese afternoon trading today.

The approval of this new indication for Xtandi triggers $90 million in milestone payments to Medivation under its collaboration agreement with Astellas.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical